SH
Therapeutic Areas
Bitterroot Bio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Anti-CD47 Therapy | Atherosclerosis / Prevention of Major Adverse Cardiovascular Events (MACE) | Pre-clinical |
Leadership Team at Bitterroot Bio
NL
Nick Leeper, MD
Co-Founder, Chief of Vascular Medicine at Stanford, Board Director
IL
Irving L. Weissman, MD
Co-Founder, Professor of Pathology at Stanford, Board Director
SG
Steve Gillis, PhD
Managing Director, ARCH Venture Partners; Executive Chairman of the Board